Please note that only limited free access to this journal is available in your country or territory.

To access the full content of this article you must purchase it (US$9.49). After payment of this one-off fee, you will gain unrestricted online access to the article and a PDF version sent to your email.

As part of our special introductory offer, after purchasing this article you will have unrestricted access to all the articles in this issue for free!

Registered users can purchase/access the article by logging in below. To register for free click here

Registered users login here:

  • Email Address:
     
  • Password:
     
  •  
If you have forgotten your password click here
0 rating

Introduction of Rivaroxaban in an Orthopedic Department

Alain Borgeat, MD, PhD

Rivaroxaban is a new antithrombotic drug that has been shown to provide superior efficacy to enoxaparin without increasing the risk of bleeding after major lower limb surgery. The introduction of this drug in a surgical department represents a paradigm change, since rivaroxaban is not administered preoperatively but postoperatively, and is not given subcutaneously but orally. These subtle changes require a complex process for its introduction in an orthopedic department to avoid severe complications caused by human error. This article presents the experience with this change in one hospital orthopedic department. Adv Venous Arterial Thromb 2011;1(1):18–24.

Please login or register to continue reading this article
Return to top
Login/Register

Post Page On

LATEST ARTICLES

Our most popular articles